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Abstract 
This report presents the case of a 78-year-old female with hepatic encephalopathy due 
to an inferior mesenteric venous-inferior vena cava shunt. She developed hepatocellular 
carcinoma affected by hepatitis C virus-related cirrhosis and underwent posterior 
sectionectomy. Portal vein thrombosis developed and the portal trunk was narrowed 
after hepatectomy. Portal vein thrombosis resulted in high portal pressure and increased 
blood flow in an inferior mesenteric venous-inferior vena cava shunt, and hepatic 
encephalopathy with hyperammonemia was aggravated. The hepatic encephalopathy 
aggravated by portal vein thrombosis was successfully treated by balloon-occluded 
retrograde transvenous obliteration via a right transjugular venous approach without the 
development of other collateral vessels. 
Introduction 
A porto-systemic shunt often causes hepatic encephalopathy with high systemic blood 
ammonia in cirrhotic patients [1, 2]. Medical therapies, such as treatment with lactulose 
and oral branched-chain amino acid supplementation, have a limited effect in patients 
with porto-systemic shunt [2]. Obliteration of the porto-systemic shunt is one possible Case Rep Gastroenterol 2011;5:366–371 
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treatment for porto-systemic shunt encephalopathy, and balloon-occluded retrograde 
transvenous obliteration (B-RTO) is an effective treatment for porto-systemic shunt 
encephalopathy [3–5] in addition to its application for the treatment of gastric varices [6]. 
Obliteration of porto-systemic shunt by B-RTO provides portal blood flow and 
transiently increases portal pressure [3, 7]. Providing patients with the capacity to buffer 
high portal pressure and increased hepatic blood flow allows recovery of their liver 
function including hepatic encephalopathy [3, 8]. However, patients who cannot buffer 
high portal pressure and increased portal blood flow are decompressed by the 
development of alternate collaterals such as esophageal varices or other collaterals [7], 
increasing the risk of bleeding and/or hepatic encephalopathy and ascites. Therefore, 
B-RTO for patients with portal trunk obstruction caused by thrombosis or tumor 
thrombosis has difficulties. 
This report presents a case of hepatic encephalopathy aggravated by portal vein 
thrombosis (PVT) successfully treated by B-RTO via a transjugular vein approach. 
Case Report 
A 78-year-old female with hepatitis C virus-associated liver cirrhosis developed hepatocellular 
carcinoma and underwent posterior sectionectomy. The patient was admitted to the hospital 
2 months later with hepatic encephalopathy (stage 1–2 by West Haven criteria) and a high systemic 
blood ammonia level (246 μg/dl). Liver function was Child-Pugh B (total bilirubin 1.7 mg/dl, albumin 
2.5 g/dl, prothrombin time 68%, with mild ascites). In addition, she had extreme edema in both lower 
extremities. Multi detector-row computed tomography (MD-CT) and three-dimensional angiography 
by MD-CT revealed a porto-systemic shunt from the inferior mesenteric vein (IMV) draining to the 
inferior vena cava (IVC) (fig. 1a). PVT had developed on the portal trunk and the portal trunk was 
narrowed. 
Anticoagulation therapy was initiated with heparin (10,000 U/day intravenously) followed by 
warfarin. The dosages of warfarin were adjusted to achieve an international normalized ratio of 
approximately 2.0 [9]. However, the PVT did not improve and the hepatic encephalopathy persisted. 
The resistance to anticoagulation therapy was thought to be caused by decreased portal venous blood 
flow accompanied by increased blood flow of IMV-IVC shunt aggravated by PVT. Therefore, B-RTO 
was performed to obliterate the IMV-IVC shunt via the right transjugular vein approach. B-RTO was 
performed as described previously [6]. A balloon catheter for B-RTO (6.5 French; Create Medic, Tokyo, 
Japan) was introduced into the IMV-IVC shunt via the right transjugular vein and the shunt was 
visualized using iopamidol. The IMV-IVC shunt was confirmed to be the only route, and the draining 
blood flow was blocked by inflating the balloon. 40 ml of 50% glucose and 2 ml of absolute ethanol were 
injected, and 15 ml of 5% ethanolamine oleate with iopamidol was injected slowly in a retrograde 
manner (fig. 1b). Simultaneously, 4,000 U of haptoglobin (Yoshitomi, Osaka, Japan) was administered 
intravenously for protection against renal damage by the ethanolamine oleate sclerosant [10]. The 
balloon was deflated 24 h after the injection of the sclerosant. 
The clinical symptoms of hepatic encephalopathy completely disappeared (stage 0 by West Haven 
criteria) 2 weeks after the treatment, and the serum ammonia level decreased immediately (fig. 2a). 
Serum total bilirubin decreased and albumin increased after the treatment (fig. 2b, c). These results were 
sustained over a 5-month follow-up. Contrast-enhanced CT scans performed 2 weeks after B-RTO 
revealed that the narrowed portal trunk and the left branch was expanded (fig. 3a, b), accompanied by 
embolization of the IMV-IVC shunt (fig. 3c). In addition, the edema in both lower extremities and 
ascites disappeared after treatment. Contrast-enhanced CT and upper gastrointestinal endoscopy 
revealed no evidence of esophageal varices and/or gastric varices or other collateral vessels. 
Anticoagulation therapy with warfarin was continued at dosages of warfarin adjusted to achieve an 
international normalized ratio of approximately 2.0. Case Rep Gastroenterol 2011;5:366–371 
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Discussion 
B-RTO is an effective treatment for gastric varices [6] and porto-systemic shunt 
encephalopathy [3, 8] associated with portal hypertension. Various collateral pathways 
of porto-systemic shunts contribute to hepatic encephalopathy, and the frequency of 
collateral pathways associated with the IMV is about 13% [11]. The drainage veins of 
these shunts include: direct shunt to the IVC, left gonadal vein, left internal iliac vein, 
and right gonadal vein. B-RTO is usually performed through the femoral vein. However, 
other approaches or other treatment modality, such as surgical ligation, must be 
considered when the porto-systemic shunt in not accessible from the femoral vein. A 
right transjugular venous approach enabled safe and effective obliteration of the 
IMV-IVC shunt in the current patient. Only in a few cases was the transjugular vein 
approach used for B-RTO [12]. 
PVT is not an uncommon complication in patients with liver cirrhosis, and its 
incidence ranges from 2 to 26% [9, 13]. Abdominal surgery, such as splenectomy, is 
associated with the development of PVT [9], however few patients develop PVT after 
hepatectomy [14, 15]. Portal pressure increases with PVT and alternate collaterals 
such as esophageal varices or other collaterals [7] develop to decompress the high portal 
pressure, which results in decreased portal flow. Since decrease in portal flow is one of the 
predisposing factors for PVT, patients may present resistance to anticoagulation therapy, 
as observed in the current patient. 
Obliteration of a porto-systemic shunt by B-RTO transiently increases portal blood 
flow and portal pressure [3, 7]. Liver function, including hepatic encephalopathy, is often 
recovered when the patients have the capacity to buffer high portal pressure and increased 
hepatic blood flow [3, 8]. Therefore, B-RTO was applied to obliterate the porto-systemic 
shunt in the current patient to treat hepatic encephalopathy and to increase portal blood 
flow, followed by immediate anticoagulation therapy. The hepatic encephalopathy 
disappeared as expected and the narrowed portal flow expanded despite the development 
of PVT. In addition, the serum albumin level increased and the edema of both lower 
extremities and ascites disappeared. Those results occurred as a result of increased portal 
blood flow. Furthermore, other no collateral vessels or esophageal varices developed. 
However, PVT persisted, requiring anticoagulation therapy. Therefore, patients 
aggravated high porto-systemic shunt blood flow with acute PVT may be immediately 
treated with B-RTO. 
This report presented a case of hepatic encephalopathy aggravated by PVT who was 
successfully treated by B-RTO via a transjugular venous approach. 
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Fig. 1. MD-CT revealed a porto-systemic shunt from the inferior mesenteric vein (IMV) draining to 
the inferior vena cava (IVC) with narrowed portal trunk (a). The draining blood flow of the IMV-IVC 
shunt was blocked by inflating the balloon, and 15 ml of 5% ethanolamine oleate with iopamidol was 
injected slowly in a retrograde manner (b). 
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Fig. 2. The serum ammonia level decreased immediately after B-RTO (a). Serum total bilirubin level 
decreased and albumin level increased after the treatment (b, c). These results were sustained over a 
5-month follow-up. 
 
 
Fig. 3. Contrast-enhanced CT scans performed 2 weeks after the B-RTO revealed that the narrowed 
portal trunk and the left branch were expanded (a, b), accompanied by embolization of the IMV-IVC 
shunt (c). 
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